Tango Therapeutics announced encouraging Phase I/II activity for its MTA‑cooperative PRMT5 inhibitor vopimetostat in MTAP‑deleted pancreatic ductal adenocarcinoma and set a pivotal Phase III start for next year. The company simultaneously closed a $225 million financing to fund the development push. Management cited response rates and progression‑free survival that exceeded chemotherapy benchmarks as the rationale to move into registrational testing for a historically refractory tumor type.